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1. Introduction  
Increased intraocular pressure and glaucoma following corticosteroid therapy are well 
known issues for the ophthalmologist for more than 50 years. Corticosteroids use has gained 
popularity in ophthalmology as anti-inflammatory and anti-allergic agents but can have 
important consequences and should be used only with judicious monitoring. The 
therapeutic use of corticosteroids can lead to the development of ocular hypertension and 
iatrogenic open-angle glaucoma in susceptible individuals. It can occur in any age group, 
either gender and from steroid therapy for any ocular or systemic disease and by any route 
of administration: topical, systemic or inhaled.  
2. Epidemiology 
About one in every three people is considered a potential "steroid responder", but only a 
small percentage will have a clinically significant elevation in intraocular pressure. 5-6% of 
the normal population develops a marked increase in intraocular pressure of more than 31 
mmHg after 4-6 weeks of topical corticosteroids therapy. 33% are moderate responders 
(elevation of 6-15 mmHg) and the remaining are considered non responreds (less than 
6mmHg of elevation in intraocular pressure). Although approximately 30%–40% of the 
normal population are “steroid responders” (i.e., develop reversible steroid-induced ocular 
hypertension), most of primary open angle glaucoma patients or with a family history are 
steroid responders. Normal individuals who are steroid responders are at higher risk for 
subsequently developing primary open angle glaucoma. In one study, high corticosteroid 
responders (intraocular pressure greater than 31 mm Hg during dexamethasone 
administration qid for 6 weeks), 13.0% developed glaucomatous visual field loss during the 
follow-up period of 5 years.  In steroid induced glaucoma patients, glaucoma is triggered by 
steroid treatment, and intraocular pressure will not decrease after cessation of steroid 
application. Thus, steroid induced glaucoma patients necessitate anti-glaucoma medications 
to control intraocular pressure. Steroid responsiveness appears to be heritable, however low 
concordance of pressure response in monozygotic twins to topical testing may indicate a 
limited role for a genetic basis. In addition highly myopic patients and diabetic patients 
have a higher rate of elevated intraocular pressure response to topical steroids.  
Age is also an important factor. In pediatric patients taking oral prednisone for 
inflammatory bowel disease 32% were steroid responders. When children younger than 10 
years of age where treated with topical instillation of dexamethasone, marked elevation in 
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intraocular pressure was noted. A dose-dependent hypertensive pressure response occurs 
more frequently, more severely and more rapidly in children than in adults. 
3. Pathophysiology  
There have been reports suggesting that endogenous cortisol may play a role in the 
pathogenesis of primary open angle glaucoma. Excess endogenous production of 
glucocorticosteroids (Cushing's syndrome) can also cause increase in intraocular pressure.  
Glucocorticosteroids alter several trabecular meshwork cellular functions including 
inhibition of cellular proliferation, migration, phagocytosis, and increased cell and nucleus 
size. Glucocorticosteroids also increase extracellular matrix synthesis and decrease its 
turnover. 
Many mechanisms have been proposed to explain the elevated intraocular pressure in 
response to glucocorticosteroids. One hypothesis is that glucocorticosteroids protect the 
lysosomal membrane and thus inhibit release of hydrolases responsible of depolimerization 
of glycosaminoglycans. Accumulated glycosaminoglycans in the ground substance of the 
outflow pathways retain water and narrow the trabecular spaces, causing increase in 
outflow resistance. In steroid-induced glaucoma there is also an increase in fine fibrillar 
material in the subendothelial region of Schlemm's cannal. These fibrils are deposited 
underneath the inner wall endothelium. The main finding in steroid-induced glaucoma is an 
accumulation of basement membrane-like material staining for type IV collagen. These 
accumulations are found throughout all layers of the trabecular meshwork.  
There are multiple isoforms of the glucocorticoid receptor (GR) a ligand-dependent 
transcriptional factor that activates or represses gene transcription. GRα is the ligand 
binding form of the receptor that is responsible for the physiologic and pharmacological 
effects of glucocorticosteroids. Most of the physiological and pharmacological effects of 
glucocorticosteroids are directly mediated by GRα. GRα resides predominantly in the 
cytoplasm in the absence of ligand as a multiprotein heterocomplex that contains Hsp 90, 
Hsp 70 and other proteins. Steroid binding to GRα causes a conformation change and 
activation of the receptor. Activated GRα can alter gene expression via GRE-dependent 
(classical) and GRE-independent (nonclassical) mechanisms. In the GRE-dependent 
pathway activated GRα translocates to the nucleus along microtubules. GRα bind to specific 
palindromic DNA sequence (GRE) as a homodimer on the promoter region of target genes 
to induce transcription. In addition, GRα functions as a negative regulator of transcription 
in a specific subset of genes that contains a negative GRE. The GRE-independent pathway is 
an additional way to inhibit gene expression. GRα physically interacts with other 
transcription factors to prevent them from binding to their response elements of genes that 
encode for proinflammatory cytokines. The anti-inflammatory and immune suppression are 
mediated via this GRE-independent pathway.  GRβ is an alternatively spliced form of the 
receptor, that resides in the nucleus, which lacks the conventional ligand binding domain, 
does not bind glucocorticosteroids, and acts as a dominant negative regulator of 
glucocorticosteroids activity. Increased expression of GRβ  appears to be responsible for 
unresponsiveness to anti-inflammatory therapy for asthma, inflammatory bowel disease 
rheumatoid arthritis and ulcerative colitis. Recent work has shown that glaucomatous 
trabecular meshwork cells have lower levels of GRβ compared with normal trabecular 
meshwork cells, and this appears to be responsible for increased glucocorticosteroids 
sensitivity in the glaucomatous trabecular meshwork cells. In primary open angle glaucoma 
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an abnormal accumulation of dihydrocortisol may potentiate exogenous glucocorticosteroids 
activity and increased intraocular pressure.  
Changes in protein synthesis have also been implicated in steroid induced glaucoma. MYOC 
gene, located on chromosome 1, encodes a secretory glycoprotein of 504 amino acids named 
Myocilin, and is the first gene to be linked to juvenile open-angle glaucoma and some forms 
of adult-onset primary open-angle glaucoma. The gene was identified as an up regulated 
molecule in cultured trabecular meshwork cells after treatment with dexamethasone and 
was originally referred to as trabecular meshwork-inducible glucocorticoid response (TIGR). 
Interestingly, the profile of MYOC up regulation by dexamethasone is in a dose- and time-
dependent manner very similar to the course of development of steroid induced glaucoma. 
This led many investigators to believe that an increased MYOC level is a cause of glaucoma. 
However, a putative association between MYOC induction and primary open angle 
glaucoma has not been firmly established.  
Glucocorticosteroids inhibit prostaglandin synthesis by trabecular cells. Prostaglandins E2 
and F2a normal function is to lower the intraocular pressure by increasing the outflow 
facility. Endothelial cells of the trabecular meshwork can act as phagocytes of debris. 
Glucocorticosteroids can suppress phagocytic activity causing accumulation of debris in the 
trabecular meshwork and decrease in outflow facility.  
In a study on rabbit eyes, after topical treatment with dexamethasone, Transmission electron 
microscopy showed increased abnormality of nucleus of the trabecular meshwork cells, 
microfilament and microtubules among interstitial cells also increased, cytoplasmic 
vacuolation, rough endoplasmic reticulum expansion, as well as an increase in intercellular 
amorphous material. The mechanism of elevated intraocular pressure is thought to be 
increased aqueous outflow resistance owing to an accumulation of extracellular matrix 
material in the trabecular meshwork (fig 1).  
 
 
Fig. 1. Light microscopic pictures of the trabecular meshwork from steroid-induced 
glaucoma (SG). a) (Right eye in case 1), b) (Case 2): Schlemm‘s canal (SC) is open. The 
intertrabescular spaces in the outer part of the TM are filled with the homogeneous 
extracellular matrix (ECM) (asterisks). Azure II staining. Scale bars indicate 50 μm for a) and 
20 μm for b) 
Effects of Glucocorticosteroids are mediated by the Glucocorticosteroids receptor, which is a 
ligand-dependent transcription factor altering the expression of trabecular meshwork genes. 
Glucocorticosteroids increase the expression of extracellular matrix (collagen, fibronectin, 
laminin), proteinase inhibitor genes (Serpina3) and decreased expression of proteinase genes 
(MMP1, TPA). Altered expression of cytoskeletal genes (ACTA2, FLNB, and NEBL) may be 
associated with Glucocorticosteroids mediated reorganization of trabecular meshwork cell 
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microfibrils and microtubules. Glucocorticosteroids reorganizes the actin cytoskeleton to 
form cross-linked actin networks (CLANs) in cultured trabecular meshwork cells, and is 
reversible after Glucocorticosteroids withdrawel. In addition Glucocorticosteroids alters 
microtubules to form microtubule tangles. 
4. Routes of corticosteroid administration 
4.1 Topical route 
Topical route includes ocular drops and ointments. Of various routes of administration, 
topical therapy most commonly induces elevated intraocular pressure and correlates with 
the duration and frequency of administration. Dexamethasone and prednisolone increase 
intraocular pressure more frequently than loteprendol (Lotemax), fluorometholone (FML), 
rimexolone (Vexol) or hydrocortisone. Fluorometholone (FML) in particular is less likely to 
increase intraocular pressure but is also a less potent steroid (table 1). Rimexolone has a low 
intraocular pressure elevating potential comparable to that of fluorometholone in adults. 
The chemical structure is responsible to the lower propensity to increase intraocular 
pressure of some steroids. Loteprendol is a site-active steroid that contains an ester rather 
than a ketone group at the C-20 position, rendering de-esterification to an inactive 
metabolite. It is highly lipid-soluble, with enhanced penetration into cells. Loteprendol 
appears to have an improved safety profile compared with ketone corticosteroids. 
Fluorometholone is deoxygenized at the C-21 position. Rimexolone lacks a hydroxyl 
substituent at the C-21 position. It has lower aqueous solubility and increased lipophilicity. 
It appears that the potency of topical steroids is directly correlated with the propensity to 
elevate intraocular pressure. Intraocular pressure elevation almost never occurs in less than 
5 days and rarely in less than 2 weeks of steroid treatment. However, late rise in ocular 
pressure is not uncommon, even if intraocular pressure has been within normal limits 
during a treatment course of 6 weeks.   
4.2 Intraocular route 
Before the advent of anti VEGF, intravitreal steroid injections have been used largely in the 
treatment of exudative age related macular degeneration, chronic cystoid macular edema, 
proliferative diabetic vitreoretinopathy, retinal vascular occlusion and chronic uveitis. Rise 
in intraocular pressure is dependent on dose, presence of aphakia or pseudophkaia and a 
history of vitrectomy, facilitating penetration of the drug into the anterior segment. 
Intraocular pressure may rise in 30-50 % of patients as soon as 1-4 weeks after intravitreal 
injection of triamcinolone acetonide (Kenalog) and often returns to baseline several months 
after injection. It is advisable to perform a trial of topical prednisolone acetate before 
intravitreal triamcinolone acetonide injection is performed. 
Fluocinolone acetonide intravitreal implants are an effective therapy for non-infectious 
posterior uveitis. However, patients receiving this treatment are at high risk for 
development of vision-threatening increased intraocular pressure. Therefore, patients 
treated with these implants should have frequent intraocular pressure monitoring. 
Intractable glaucoma may necessitate removal of the depot by pars plana vitrectomy to 
lower intraoculare pressure. In the SCORE study grid photocoagulation and repeated 
injections of triamcinolone acetonide 1 or 4 mg seemed to be equally effective in producing 
improvements in best corrected visual acuity in patients with macular edema due to branch 
retinal vein occlusion. 41% of patients treated with triamcinolone acetonide 4 mg initiated 
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intraocular pressure lowering medications during the 12 months study. In patient with 
central retinal vein occlusion 35% of the patients receiving 4 mg triamcinolone acetonide 
initiated glaucoma medications. Ozurdex is a slow release intravitreal implant of 
dexamethasone currently under clinical trials for the treatment of macular edema in retinal 
vein occlusion disease. It appears that the dexamethasone implant is well tolerated, 
producing transient, moderate and readily managed increase in intraocular pressure in less 
than 16% of eyes.    
4.3 Periocular route 
Subconjunctival, sub-Tenon and retrobulbar injections of triamcinolone acetonide may cause 
dangerous and prolonged elevation of intraocular pressure because of their long duration of 
action. Surgical excision of sub-Tenon triamcinolone acetonide deposit should be considered 
if the primary treatment for steroid-induced glaucoma is refractory to medical treatment.  
The application of topical corticosteroids to the eyelids and periorbital region, in the 
treatment of atopic dermatitis, even over long periods of time, was not related to the 
development of glaucoma or cataracts. 
4.4 Systemic route 
Systemic administration includes ingestion, inhalation and nasal spray. It is less likely to 
cause intraocular elevation. However, intraocular pressure may rise weeks to years after 
treatment. When administrated concurrently with topical steroids it may have an additive 
effect and higher intraocular pressure than a single route. 
Intranasal corticosteroids have become a gold standard in therapy for allergic 
rhinoconjunctivitis and recent evidence indicates that may be effective at alleviating ocular 
symptoms as well. Intranasal corticosteroids are absorbed systemically in small measurable 
amounts. Some studies suggest a relationship between intranasal steroids and increased 
intraocular pressure. 
Aerosolized drugs delivered with a facemask may inadvertently deposit in the eyes, raising 
concerns about ocular side effects. Inhaled corticosteroids have been associated with an 
increased risk of skin thinning, bruising, cataracts and possibly glaucoma in adults. The 
risks increase with advanced age, higher doses, and longer duration of use. In children, the 
risks of cataracts and glaucoma were negligible with inhaled corticosteroids, whether a 
mouthpiece or a mask interface was used. It is not known whether exposed children will 
have increased risks from inhaled corticosteroids later in life. Therefore, it is wise to avoid 
face and eye deposition when possible, to use the minimally effective dose and a regular 
follow up of intraocular pressure. 
4.5 Endogenous route 
Elevated blood levels of corticosteroids of endogenous production, as seen in adrenal 
hyperplasia or neoplasia (Cushing syndrome) can also cause increase in the intraocular 
pressure. After adrenalectomy, increased intraocular pressure may retune to normal values 
5. Clinical course 
An increase in intraocular pressure may occur days to weeks and even months after the 
administration of steroids. The increase in intraocular pressure depends on potency, 
penetration, frequency and route of administration. Individual susceptibility, older age and 
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ocular disease are also important factors. An acute presentation may occur after intense 
systemic steroid therapy. Patient may complain on pain, decreased vision and conjunctival 
hyperemia. In infants the clinical picture may resemble that of congenital glaucoma. Signs 
are tearing, Descement's membrane breaks, corneal edema, enlarged corneal diameter, 
elevated intraocular pressure and optic disc cupping. Unlike congenital glaucoma, the 
anterior chamber angle is normal. 
 
 
Potency 
 
 
Steroid 
 
Glaucoma risk 
 
High 
 
Betamethasone  
Clobetasol propionate 
Dexamethasone  
Flucinonide  
 
Medium 
 
Triamcinolone acetonide  
Loteprendole etabonate  
Dexamethasone sodium phosphate  
Fluormethalone  
 
Low 
 
Hydrocortisone  
Rimexolone  
Medrisone  
 
Table 1. Comparison of anti-inflamatory and intraocular pressure elevating potencies 
Additional ocular findings from topical steroids include corneal ulcers, exacerbation of 
bacterial and viral infections, posterior subcapsular cataracts, mydriasis, delayed wound 
healing, scleral melting ptosis and skin atrophy and depigmentation of the eyelids. Systemic 
steroids side effects are suppression of the pituitary-adrenal axis, Cushinoid facies, buffalo 
hump, truncal obesity, hirsutism, cutaneous striae, easy bruisability, delayed wound 
healing, osteoporosis,  aseptic necrosis of the hip, peptic ulcers, diabetes, hypertension, 
insomnia and psychiatric disorders. 
6. Management  
This secondary glaucoma clinically mimics many features of primary open angle glaucoma. 
Currently, the propensity to develop steroid-induced ocular hypertension must be 
determined empirically. Therefore, all patients on protracted steroid therapy should have 
their intraocular pressure monitored periodically. 
Steroid induced glaucoma usually responds to cessation of steroid therapy and to topical 
anti-glaucoma medication. In steroid responders the intraocular pressure generally returns 
to normal within few days to weeks after discontinuation of steroids. Rarely, intraocular 
pressure remains elevated despite steroid cessation and may result from damage to outflow 
channels. In these cases management is similar to that of open angle glaucoma patients. 
If anti-inflammatory therapy is needed in known steroid responders or glaucoma patients, 
treatment with FML 0.1% or medrisone (MHS) are possible options. Loteprendol (Lotemax) 
and Rimexolone (Velox) are potent anti-inflammatory corticosteroids with reduced 
propensity to raise intraocular pressure.  
www.intechopen.com
 
Steroid Induced Glaucoma 
 
565 
Alternative topical anti-inflammatory agents are the nonsteroidal anti-inflammatory agents 
(NSAIDs), such as diclofenac (Voltaren), ketorolac tromethamine (Acular LS) and bromfenac 
(Xibrom). NSAIDs do not induce increase in intraocular pressure but their anti-
inflammatory potential is lower than that of corticosteroids. 
When indicated, topical anti-glaucoma medications should be used. Prostaglandins should 
be used with caution as they may have pro-inflammatory effect. If intraocular pressure 
remains intractable despite maximal tolerated medical therapy, Argon laser trabeculoplasty 
and Nd:YAG laser selective trabeculoplasty (SLT) have variable success and patients 
required additional surgical procedures. Repeat SLT treatments may be necessary. SLT is a 
temporizing procedure to consider in patients with steroid-induced elevated IOP. 
A possible new treatment under investigation is anecortave acetate injection into the 
anterior sub-Tenon space in eye with uncontrolled steroid-related ocular hypertension 
following intravitreal or sub-Tenon injections of triamcinolone acetonide. Anecortave 
acetate is a synthetic molecule derived from cortisol. The resulting molecule is referred to as 
a cortisene. The modification renders the molecule free of all glucocorticoid and 
mineralocorticoid activity. Anecortave acetate possesses antiangiogenic activity via 
inhibition of the proteases necessary for vascular endothelial cell migration and has been 
evaluated as a potential therapy for neovascular age-related macular degeneration. In one 
preliminary, uncontrolled study a rapid and sustained reduction of intraocular pressure was 
noted as soon as 1 week after treatment. The mechanism by which anecortave acetate lowers 
intraocular pressure in eyes with steroid-related ocular hypertension is unknown. With 
glucocorticoid treatment, trabecular meshwork cells increases the expression of 
plasminogen activator inhibitor–1, a protein that inhibits activation of extracellular 
proteinases and leads to enhanced extracellular matrix deposition. Recent studies have 
shown that anecortave acetate blocks glucocorticoid induction of plasminogen activator 
inhibitor–1, which may be partially responsible for anecortave acetate's intraocular pressure 
lowering activity. 
Surgical treatments include filtration surgery, tube shunt, excision of the  sub-Tenon steroid 
depot, explantation of steroid implant  and pars plana vitrectomyfor the removal of the 
intravitreal depot. 
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